This is a transformative reverse-merger for CMMB, which will deliver a ~$150M combined entity with $30M+ in new cash and a clear pipeline catalyst in RA. The merger provides a path to a Nasdaq listing as SCIP with institutional sponsorship. Monitor the shareholder vote, SEC S-4 filing, and Israeli tax ruling as near-term catalysts. The transition from CMMB to SCIP creates an event-driven opportunity for long-biased traders willing to hold through the Q4 2026 close window.
Price Chart
Executive Summary
Chemomab Therapeutics (CMMB) entered into a definitive merger agreement to be acquired by Scipher Medicine Corporation, a precision medicine company. The combined company, valued at $150 million, will operate as Scipher Medicine Corporation and trade under the ticker SCIP. Chemomab shareholders will own approximately 32% of the combined company before a concurrent $30 million PIPE. The merger is expected to close in Q4 2026.
Key Facts
- Combined company pre-money valuation of $150 million ($48 million for Chemomab, $102 million for Scipher, subject to adjustment for Scipher's indebtedness)
- Chemomab equity holders expected to own approximately 32% of combined company; Scipher equity holders approximately 68%, pre-PIPE
- Concurrent PIPE investment of not less than $30 million from a syndicate led by Northpond Ventures including Khosla Ventures, Blue Owl Healthcare Opportunities, and funds managed by Neuberger
- Post-merger company to focus on advancing nebokitug into a Phase 2 RA trial with AI-powered precision medicine enrollment using Scipher's PrismRA test
- Phase 2 RA readout expected H1 2028; cash runway expected into H2 2028
- Chemomab pre-merger shareholders to receive CVRs for cash payments upon achievement of nebokitug milestones
- Merger expected to close in Q4 2026; combined company to trade under ticker SCIP on Nasdaq
Financial Impact
Combined company valued at $150 million pre-PIPE; Chemomab valued at $48 million, Scipher at $102 million (subject to adjustment for Scipher's indebtedness). Concurrent PIPE of at least $30 million at a valuation of $150 million with 100% warrant coverage at 50% of the PIPE valuation.
Risk Factors
- Transaction may not close due to failure of shareholder approval, regulatory hurdles, or failure to obtain Israeli tax rulings: $2M termination fee payable by Chemomab to Scipher in certain events
- Chemomab must have Net Cash of at least $0 at closing; no Indebtedness
- Phase 2 RA data readout not expected until H1 2028—several years away
- Lock-up agreements restrict selling by key Chemomab and Scipher insiders after closing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003442 |
| Exhibit: exhibit_99-1.htm | 0001178913-26-003442 |
| Document: zk2635653.htm | 0001178913-26-003442 |
| Document: 0001178913-26-003442-index-headers.html | 0001178913-26-003442 |
| Document: 0001178913-26-003442-index.html | 0001178913-26-003442 |
| Document: 0001178913-26-003442.txt | 0001178913-26-003442 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | 6-K | $2.09 $2.80 | ▲ +33.97% | ▲ +35.92% | $1.30 (−37.80%) |
Aug 19, 2026 6w ago | Press Release | $2.09 $2.80 | ▼ −33.97% | ▼ −35.92% | $1.30 (+37.80%) |
Jul 8, 2026 12w ago | 6-K | $1.97 $1.75 | ▼ −11.17% | ▼ −14.44% | $1.30 (−34.01%) |
Jun 2, 2026 17w ago | 6-K | $1.72 $2.27 | ▲ +31.98% | ▲ +32.98% | $1.30 (−24.42%) |
May 14, 2026 20w ago | 6-K | $1.70 $1.65 | ▼ −2.94% | ▼ −2.08% | $1.30 (−23.53%) |
May 14, 2026 20w ago | Press Release | $1.70 $1.65 | ▼ −2.94% | ▼ −2.08% | $1.30 (−23.53%) |
May 6, 2026 21w ago | 6-K | $1.74 $1.72 | ▼ −1.15% | ▼ −4.29% | $1.30 (−25.29%) |
Mar 19, 2026 28w ago | Press Release | $1.93 $1.67 | ▼ −13.47% | ▼ −21.09% | $1.30 (−32.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access